SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-045948
Filing Date
2023-12-22
Accepted
2023-12-22 16:45:17
Documents
13
Period of Report
2023-12-22
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43199
2 ex16-1.htm EX-16.1 3805
  Complete submission text file 0001493152-23-045948.txt   224270

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE zvsa-20231222.xsd EX-101.SCH 3012
4 XBRL LABEL FILE zvsa-20231222_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE zvsa-20231222_pre.xml EX-101.PRE 22357
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3471
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 231510469
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)